title: Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma.
abstract: The goal of this study was to use dose-intensity analyses of published Ewing's sarcoma and osteogenic sarcoma trials to determine which agents were most closely associated with a favorable response. The percentage of patients with more than 90% tumor necrosis following neoadjuvant chemotherapy was the end point for analysis of osteogenic sarcoma trials, and disease-free survival and percentage of patients with distant-only relapse were the end points for analysis of Ewing's sarcoma trials. The data were analyzed using logistic regression analysis to circumvent the distortion of univariate analysis resulting from the correlation between doxorubicin dose intensity and the dose intensity of other agents. Our analysis suggests that doxorubicin dose intensity is an important determinant of favorable outcome for both Ewing's sarcoma and osteogenic sarcoma and that the dose intensities of other agents do not contribute as significantly to outcome as does doxorubicin dose intensity. Increasing dactinomycin dose intensity was associated with a poorer outcome in treatment of osteogenic sarcoma and Ewing's sarcoma, most likely resulting from regimens with a higher dactinomycin dose intensity having a lower doxorubicin dose intensity. While our analysis of osteogenic sarcoma trials is consistent with significant activity for cisplatin and high-dose methotrexate (and likely ifosfamide), a rank ordering of the efficacy of these agents when given with doxorubicin in multiagent regimens is not possible. Our analysis illustrates the importance of analyzing the contributions of individual agents to combination chemotherapy regimens. In the design of future clinical trials for osteogenic sarcoma and Ewing's sarcoma, careful attention should be given to optimizing doxorubicin dose intensity in regimens to be tested.
authors.affiliation: Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892.
authors.forename: M A
authors.initials: MA
authors.lastname: Smith
authors.forename: R S
authors.initials: RS
authors.lastname: Ungerleider
authors.forename: M E
authors.initials: ME
authors.lastname: Horowitz
authors.forename: R
authors.initials: R
authors.lastname: Simon
mesh_terms: D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage*; D006801:Humans; D015201:Meta-Analysis as Topic; D012516:Osteosarcoma / Q000188:drug therapy*; D011379:Prognosis; D012044:Regression Analysis; D012512:Sarcoma, Ewing / Q000188:drug therapy*; D016019:Survival Analysis
chemical_list: D004317:Doxorubicin